Zhong Zhao
Amministratore Delegato presso ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Patrimonio netto: 130 M $ in data 30/04/2024
Posizioni attive di Zhong Zhao
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. | Amministratore Delegato | 06/11/2012 | - |
| Presidente | 06/11/2012 | - | |
| Fondatore | 06/11/2012 | - | |
| AVINGER, INC. | Direttore/Membro del Consiglio | 05/03/2024 | - |
| Independent Dir/Board Member | 05/03/2024 | - |
Storia della carriera di Zhong Zhao
Precedenti posizioni note di Zhong Zhao
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Cordis Corp.
 Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | Corporate Officer/Principal | 01/07/2002 | 01/08/2011 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | 01/07/1996 | 01/06/2002 |
Formazione di Zhong Zhao
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Cina | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
| Chairman | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. | Health Technology |
| AVINGER, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | Health Technology |
- Borsa valori
- Insiders
- Zhong Zhao
- Esperienza